Browse every story filed under this topic, curated from trusted publishers around the world.
Atsena Therapeutics is set to proceed with the Part C cohort of its Phase I/II/III LIGHTHOUSE trial of ATSN-201 in patients with XLRS. The post Atsena secures DMC approval for LIGHTHOUSE trial appeared first on Clinical …
Read full story →You've seen all articles for #dmc.
Check back
soon
for new stories.